. Author manuscript; available in PMC: 2013 Jun 1.

Published in final edited form as: Expert Opin Emerg Drugs. 2012 Jun;17(2):261–277. doi: 10.1517/14728214.2012.691965

Table 1.

Drugs/Approaches used for utrophin upregulation

Drug/compound	Company	Status	Mode of Action
^*SMT C1100	Summit PLC.	Preclinical	Upregulation of utrophin promoter
^*BMN-195	Biomarin Pharmaceuticals	Phase I Clinical Trial	Upregulation of utrophin promoter
Nabumetone	GlaxoSmithKline	Preclinical	Upregulation of utrophin promoter
Heregulin	Sigma	Preclinical	Activation of utrophin promoter
Biglycan	Tivorsan Pharmaceuticals	Preclinical	Post-transcriptional upregulation of utrophin

SMT C1100 and BMN-195 are the same compound